Drug Combination Details
| General Information of the Combination (ID: C01021) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | Carfilzomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
| In-vitro Model | U266B1 | CVCL_0566 | Plasma cell myeloma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin significantly ameliorates CFZ cytotoxic effect. Induction of p53/p21 axis and G0/G1 cell cycle arrest were more pronounced for the CFZ-curcumin combination. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-kappaB pathways. Toxicol In Vitro. 2018 Mar;47:186-194. | |||
